Both the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) and the CD3-CD19 bispecific T-cell engager blinatumomab have single-agent activity in relapsed or refractory acute lymphoblastic leukemia (ALL). We previously reported the promising efficacy and survival of INO in combination with low-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL. In this MEDtalk Nicholas J. Short tell how toimprove these outcomes by adding blinatumomab to this regimen.
The study show, that mini-hyper-CVD + INO ± blinatumomab, is safe and effective in elderly pts with newly diagnosed Ph-negative ALL, with an overall response rate of 98% and 3-year OS rate of 54%.